Treatment approaches to IgG4-related systemic disease

Current Opinion in Rheumatology

Volumn 23, Issue 1, 2011, Pages 67-71

  Khosroshahi, Arezou ^a   Stone, John H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

autoimmune pancreatitis; B cell depletion; IgG4; IgG4 related systemic disease; rituximab

Indexed keywords

AZATHIOPRINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN G4; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RITUXIMAB;

AORTITIS; ARTICLE; AUTOIMMUNE PANCREATITIS; CHOLANGITIS; DACRYOADENITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; FOLLOW UP; GLUCOSE INTOLERANCE; HUMAN; HYPERIMMUNOGLOBULINEMIA; IMMUNOGLOBULIN G4 RELATED SYSTEMIC DISEASE; LUNG DISEASE; ORBIT PSEUDOTUMOR; PRIORITY JOURNAL; RELAPSE; REMISSION; SIALOADENITIS; SYSTEMIC DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNE DISEASES; BORONIC ACIDS; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; PANCREATITIS; PROGNOSIS; PYRAZINES; RECURRENCE;

EID: 78650460707     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328341a240     Document Type: Article

References (29)

1. Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol 2006; 4:1010-1016; quiz 934.
2. Otsuki M, Chung JB, Okazaki K, et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea Symposium on Autoimmune Pancreatitis. J Gastroenterol 2008; 43:403-408.
3. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cho-langitis: clinical profile and response to therapy. Gastroenterology 2008; 134:706-715.
4. Stone JH, Khosroshahi A, Deshpande V, Stone JR. IgG4-related systemic disease accounts for a significant proportion of thoracic lymphoplasmacytic aortitis cases. Arthritis Care Res 2010; 62:316-322.
5. Stone JH, Khosroshahi A, Hilgenberg A, et al. IgG4-related systemic disease and lymphoplasmacytic aortitis. Arthritis Rheum 2009; 60:3139-3145.
6. Zen Y, Onodera M, Inoue D, et al. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am JSurg Pathol2009; 33:1833- 1839.
7. Dahlgren M, Khosroshahi A, Nielsen GP, et al. Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken) 2010; 62:1312-1318.
8. Wakabayashi T, Kawaura Y, Satomura Y, et al. Long-term prognosis of duct-narrowing chronic pancreatitis: strategy for steroid treatment. Pancreas 2005; 30:31-39.
9. Kubota K, Iida H, Fujisawa T, et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc 2007; 66:1142-1151.
10. Park DH, Kim MH, Chari ST. Recent advances in autoimmune pancreatitis. Gut 2009; 58:1680-1689.
11. Kamisawa T, Yoshiike M, Egawa N, et al. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology 2005; 5:234-238; discussion 8-40.
12. Kamisawa T, Chung JB, Irie H, et al. Japan-Korea Symposium on Autoimmune Pancreatitis (KOKURA 2007). Pancreas 2007; 35:281-284.
13. Ito T, Nishimori I, Inoue N, et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol 2007; 42 (Suppl 18):50-58. (Pubitemid 46863938)
14. Ko SB, Mizuno N, Yatabe Y, et al. Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology 2010; 138:1988-1996.
15. Kamisawa T, ShimosegawaT, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58:1504-1507.
16. Kamisawa T, Okazaki K, Kawa S, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol 2010; 45:471-477.
17. Kim HM, Chung MJ, Chung JB. Remission and relapse of autoimmune pancreatitis: focusing on corticosteroid treatment. Pancreas 2010; 39:555-560.
18. Pannala R, Chari ST. Corticosteroid treatment for autoimmune pancreatitis. Gut 2009; 58:1438-1439.
19. Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007; 56:1719-1724.
20. Naitoh I, Nakazawa T, Ohara H, et al. Autoimmune pancreatitis associated with various extrapancreatic lesions during a long-term clinical course successfully treated with azathioprine and corticosteroid maintenance therapy. Intern Med 2009; 48:2003-2007.
21. Church NI, Pereira SP, Deheragoda MG, et al. Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. Am J Gastroenterol 2007; 102:2417-2425.
22. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355:1772-1779.
23. Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2008; 6:364-366. (Pubitemid 351318380)
24. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62:1755-1762.
25. Pennisi A, Li X, Ling W, et al. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009; 84:6-14.
26. Khan ML, Colby TV, Viggiano RW, Fonseca R. Treatment with bortezomib of a patient having hyper IgG4 disease. Clin Lymphoma Myeloma Leuk 2010; 10:217-219.
27. Ghazale A, Chari ST. Optimising corticosteroid treatment for autoimmune pancreatitis. Gut 2007; 56:1650-1652.
28. Kamisawa T, Okamoto A, Wakabayashi T, et al. Appropriate steroid therapy for autoimmune pancreatitis based on long-term outcome. Scand J Gastroenterol 2008; 43:609-613.
29. Park do H, Kim MH,Oh HB, et al., Substitution of asparticacid at position 57 of the DQbeta1 affects relapse of autoimmune pancreatitis. Gastroenterology 2008, 134 440-446.